Nkarta (NASDAQ: NKTX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.790 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Nkarta (NASDAQ: NKTX) through any online brokerage.
Other companies in Nkarta’s space includes: Cogent Biosciences (NASDAQ:COGT), Eagle Pharmaceuticals (NASDAQ:EGRX), Immatics (NASDAQ:IMTX), Adicet Bio (NASDAQ:ACET) and TG Therapeutics (NASDAQ:TGTX).
The latest price target for Nkarta (NASDAQ: NKTX) was reported by Raymond James on Tuesday, April 26, 2022. The analyst firm set a price target for 32.00 expecting NKTX to rise to within 12 months (a possible 142.79% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Nkarta (NASDAQ: NKTX) is $13.18 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Nkarta.
Nkarta’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Nkarta.
Nkarta is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.